Clinical Trials · NCT07036172
Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- Enrollment
- 460
- Start date
- Jan 2025
- Locations
- 1 site, China
- Primary endpoint
- The percentage change in body weight from baseline to week 44